Jupiter Neurosciences, Inc. filings document a clinical-stage pharmaceutical issuer with common stock listed on the Nasdaq Capital Market and a business built around the JOTROL™ resveratrol platform and Nugevia™ products. Material-event reports cover standby equity purchase and registration-rights agreements, convertible promissory notes, amendments to installment provisions, and Nasdaq continued-listing notices.
Proxy materials disclose annual meeting matters, board governance and stockholder voting procedures. Rule 12b-25 notices document delayed periodic reports for annual and quarterly filings, while capital-structure disclosures address common stock, potential share issuances and related financing limitations.
Jupiter Neurosciences entered a Standby Equity Purchase Agreement with Yorkville, giving the company the right to sell up to $20.0 million of common stock over 24 months, at its option and subject to an effective resale registration statement. Each Advance is priced at 97% of the lowest daily VWAP over a three-day period, with an optional minimum price set by the company and share caps tied to recent trading volume.
Yorkville also provided up to $6.0 million in Pre-Paid Advances via convertible notes. The first tranche of $3,720,000 funded on October 27, 2025 in exchange for a $4.0 million note issued at a 7% OID, bearing 8% interest and initially convertible at $1.50 per share, maturing October 24, 2026. A second tranche of $1,860,000 is expected after the registration becomes effective and stockholders approve issuances above the Nasdaq Exchange Cap of 7,180,504 shares (19.99%).
Until the notes are repaid, any Advances under the SEPA will be used to offset scheduled monthly Installment Amounts starting on day 75. The company issued 131,909 commitment shares (valued at $200,000) and paid a $25,000 structuring fee. Additional terms include a 4.99% beneficial ownership limit (adjustable with notice), a prohibition on new variable-rate financings, and Yorkville’s agreement not to short the stock. A stockholder vote is planned for December 19, 2025.
Jupiter Neurosciences (JUNS) filed a preliminary proxy for its 2025 virtual Annual Meeting. Stockholders are asked to elect seven directors, approve an amendment to increase authorized common stock from 125,000,000 to 500,000,000 shares, adopt the 2025 Equity Incentive Plan, and ratify Cherry Bekaert LLP as independent auditor.
The meeting will be held virtually on December 12, 2025 at 10:00 a.m. Eastern Time. The record date is October 24, 2025. The company notes that director nominees will serve until the 2026 annual meeting, and broker discretionary voting applies only to the auditor ratification proposal.
Jupiter Neurosciences, Inc. filed a notice that it will be late in submitting its Quarterly Report on Form 10-Q for the period ended June 30, 2025. The company states it could not complete the filing on time without unreasonable effort or expense.
Management explains that it needs additional time to finish preparing and reviewing its financial statements and related disclosures. The company expects to file the Form 10-Q no later than the fifth calendar day after the original due date, consistent with the extension allowed under Rule 12b-25.
Jupiter Neurosciences (JUNS) Form 4 filing: President, Chief Business Officer and Director Alison D. Silva reported three open-market purchases on 01 July 2025 totaling 750 common shares at an average price of roughly $1.03 per share. Following the transactions, Silva directly owns 112,777 shares of JUNS common stock. No derivative security activity was disclosed.
The transactions are coded “P,” indicating routine open-market buys and not part of a Rule 10b5-1 trading plan. While the dollar value is modest (≈ $770), insider buying is generally interpreted as a vote of confidence in the company’s prospects. However, the size of the purchase is immaterial to overall share count and does not meaningfully affect ownership structure.